Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamera J Corte

Showing results (81-90 of 154) with videos related to

Pageof 16
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 26, 2022
The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrumentQiang Zheng, Ingrid A Cox, Barbara de Graaff, et al.
American Journal of Respiratory and Critical Care Medicine|October 11, 2024
Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical TrialTamera J Corte, Juergen Behr, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Respirology (Carlton, Vic.)|August 18, 2020
Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinicAnna E B McLean, Susanne E Webster, Margaret Fry, et al.
Respirology (Carlton, Vic.)|December 17, 2024
Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot studyLaura M Glenn, Dan Jackson, Carly Barton, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Respirology (Carlton, Vic.)|August 16, 2014
Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative projectYuben Moodley, Nicole Goh, Ian Glaspole, et al.
Chest|May 17, 2014
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosisJade Jaffar, Sofia Unger, Tamera J Corte, et al.
BMC Pulmonary Medicine|January 27, 2018
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registryHelen E Jo, Ian Glaspole, Yuben Moodley, et al.
Pageof 16

Showing results (81-90 of 154) with videos related to

Sort By:
Pageof 16
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 26, 2022
The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrumentQiang Zheng, Ingrid A Cox, Barbara de Graaff, et al.
American Journal of Respiratory and Critical Care Medicine|October 11, 2024
Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical TrialTamera J Corte, Juergen Behr, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Respirology (Carlton, Vic.)|August 18, 2020
Priorities and expectations of patients attending a multidisciplinary interstitial lung disease clinicAnna E B McLean, Susanne E Webster, Margaret Fry, et al.
Respirology (Carlton, Vic.)|December 17, 2024
Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot studyLaura M Glenn, Dan Jackson, Carly Barton, et al.
Clinical and Experimental Rheumatology|August 6, 2015
Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Susanna M Proudman, Nicole Goh, et al.
Respirology (Carlton, Vic.)|August 16, 2014
Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative projectYuben Moodley, Nicole Goh, Ian Glaspole, et al.
Chest|May 17, 2014
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosisJade Jaffar, Sofia Unger, Tamera J Corte, et al.
BMC Pulmonary Medicine|January 27, 2018
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registryHelen E Jo, Ian Glaspole, Yuben Moodley, et al.
Pageof 16